Monday, October 25, 2021

Global Ischemia Reperfusion Injury Therapeutics Market to Surpass US$ 2,290.1 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#HeartInjury–According to Coherent Market Insights, the global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 1,582.3 million by end of 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).

Key Trends and Analysis:

Ischemia reperfusion injury (IRI) is tissue damage that arises when blood supply returns to the tissue (reperfusion) after lack of oxygen (ischemia). The symptoms of ischemia injury include hypertension, bradycardia, and seizures.

The global ischemia reperfusion injury therapeutics market is expected to witness significant growth owing to adoption of strategies such as research & development and collaborative agreements by key players. For instance, Revive Therapeutics, a life-science company focused on research & development of drugs for ischemia reperfusion injury, received the Orphan Drug Designation in November 2018 for Cannabidiol.


In May 2016, NeuroVive and Sanofi entered a collaboration agreement to develop and commercialize CicloMulsion in South Korea. CicloMulsion is indicated for treatment of ischemia and reperfusion injury (IRI) in cardiovascular diseases. Under the agreement, NeuroVive received an upfront payment and royalty on potential future sales in the country.

RELATED:  cbdMD’s CBD PM and CBD Freeze Awarded 2020 Product of the Year

Key players in the ischemia reperfusion injury market are also focused on obtaining drug approvals and clearance from regulatory authorities to maintain a competitive edge in the market. For instance, in November 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide.

Request for Sample copy @

Key Market Takeaways:

The global ischemia reperfusion injury therapeutics market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027) owing to the rising focus of key players on developing novel treatment for ischemia reperfusion injury.

North America is expected to be the most lucrative region in the global ischemia reperfusion injury therapeutics market due to the growing demand for disease-specific treatment and rising number of FDA approvals for treatment of ischemia reperfusion injury. For instance, in May 2019, Abiomed received FDA approval for its STEM DTU trial of delayed ischemic reperfusion injury with impella CP.

RELATED:  Sproutly Announces its 6th Provincial Supply Agreement

Competitive Landscape:

Key players operating in the global ischemia reperfusion injury therapeutics market are Gilead Sciences, Inc., Omeros Corporation, Ensemble Therapeutics Corporation, Nyken B.V., Erimos Pharmaceuticals, LLC, Opsona Therapeutics Limited, Curatis Pharma GmbH, Pharming Group N.V., Biomedica Management Corporation, Orexo AB, Bolder Biotechnology, Inc., PledPharma AB, Bayer AG, Proteo, Inc., Angion Biomedica Corp., Prolong Pharmaceuticals, Antipodean Pharmaceuticals, Inc., Prothix BV, Amyndas Pharmaceuticals LLC, Stealth BioTherapeutics Inc., and Zealand Pharma A/S.

Buy-Now this Research Report @

Market Segmentation:

  • Global Ischemia Reperfusion Injury Therapeutics Market, By Indication:

    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Other Injury
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Distribution Channel:

    • Retail Pharmacies
    • Hospital Pharmacies
    • Others
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Region:

    • North America

      • U.S.
      • Canada
    • Europe

      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
    • Asia Pacific

      • By Country:

        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America

      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East

      • GCC
      • Israel
      • Rest of Middle East
    • Africa

      • South Africa
      • Central Africa
      • North Africa
RELATED:  MyMD Pharmaceuticals Set to Join Russell Microcap® Index

Related Market Intelligence Report:

Chronic Liver Diseases Therapeutics Market, by Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulins, and Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.


Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Follow Us: LinkedIn | Twitter

Related Articles

Follow Us on Twitter


Latest Posts